- Conditions
- Intraocular Melanoma, Malignant Conjunctival Neoplasm, Melanoma (Skin)
- Interventions
- incomplete Freund's adjuvant, multi-epitope melanoma peptide vaccine, tetanus toxoid helper peptide, biopsy
- Biological · Procedure
- Lead sponsor
- Craig L Slingluff, Jr
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–5
of 5
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Melanoma
- Interventions
- 4-peptide and 12-peptide melanoma vaccines
- Biological
- Lead sponsor
- Craig L Slingluff, Jr
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Advanced Cancer
- Interventions
- Cohort 1 anti-OX40, Cohort 2 anti-OX40, Cohort 3 anti-OX40, Tetanus Day 29, Tetanus Day 1, KLH Day 1, KLH Day 29
- Drug · Biological
- Lead sponsor
- Providence Health & Services
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2017
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Kidney Transplantation
- Interventions
- DT, Daclizumab, KLH
- Biological · Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 2 Years to 19 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Indianapolis, Indiana • Kansas City, Missouri + 1 more
- Conditions
- Melanoma (Skin)
- Interventions
- incomplete Freund's adjuvant, melanoma helper peptide vaccine, multi-epitope melanoma peptide vaccine, tetanus toxoid helper peptide, cyclophosphamide
- Biological · Drug
- Lead sponsor
- Craig L Slingluff, Jr
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 3
- States / cities
- Philadelphia, Pennsylvania • Houston, Texas • Charlottesville, Virginia